Curia's Burlington Sterile Manufacturing Facility Wins Massachusetts Manufacturer of the Year Award
Key Insights
Curia Global (search)'s Burlington, Massachusetts sterile drug product facility received the "Manufacturer of the Year" award from the Massachusetts Legislative Manufacturing Caucus (search) at the 10th Annual Manufacturing Awards Ceremony.
The facility specializes in manufacturing vials and prefilled syringes for late-stage clinical trials and commercial products, with capabilities for complex APIs, potent compounds, and controlled substances.
The Burlington site, operational since 2010, is part of Curia's global network of four sterile fill-finish facilities spanning the US and UK, supporting pharmaceutical development from clinical to commercial scale.
Curia Global (search)'s Burlington, Massachusetts sterile drug product facility has been recognized as "Manufacturer of the Year" by the Massachusetts Legislative Manufacturing Caucus (search), highlighting the contract development and manufacturing organization's role in pharmaceutical production. The award was presented at the 10th Annual Manufacturing Awards Ceremony held at Gillette Stadium on October 21, 2025.
Specialized Manufacturing Capabilities
The Burlington facility, which has been part of Curia's network since 2010, specializes in drug product manufacturing of vials and prefilled syringes for late-stage clinical trials and commercial products. The site demonstrates advanced capabilities in handling solvent-based processes, highly viscous products, and controlled substances. Additionally, the facility houses an on-site process development laboratory that supports mixing studies, scale-up activities, and formulation development.
"Curia employees play a crucial role in producing medicines patients can trust, guided by the most stringent quality standards," said Mari-Kate Alter, General Manager and Site Head of Curia Burlington. "While our direct clients are pharmaceutical companies, we come to work each day with patients in mind. We are honored to contribute to improving patient lives and are proud to be recognized for our role in Massachusetts' manufacturing ecosystem."
Global Manufacturing Network
The Burlington site represents one component of Curia's comprehensive sterile drug product capabilities, which encompass working with complex APIs, potent and cytotoxic compounds, highly viscous formulations, and controlled substances across clinical to commercial scales. The company operates four advanced sterile fill-finish facilities worldwide, including clinical manufacturing sites in Camarillo, California and Glasgow, UK, as well as commercial and clinical capabilities in Albuquerque, New Mexico.
Industry Recognition and Economic Impact
The Massachusetts Legislative Manufacturing Caucus (search), established in 2014, comprises more than 70 Massachusetts legislators dedicated to strengthening the state's manufacturing sector through workforce training, innovation support, and apprenticeship programs. State Representative Jeffrey Roy, House Chair of the Manufacturing Caucus, emphasized the significance of manufacturers like Curia in the state's economic landscape.
"This is an exciting time for committed manufacturers like Curia who embody 'Making It in Massachusetts,'" Roy stated. "Manufacturing remains vital to our economy and future, providing innovation and high-paying jobs for residents across the Commonwealth."
Curia operates as a contract research, development and manufacturing organization with over 30 years of experience, maintaining an integrated network of 20 global sites and employing 3,200 people. The company partners with biopharmaceutical customers to advance life-changing therapies from discovery through commercialization, offering integrated regulatory, analytical, and sterile fill-finish capabilities across small molecule, generic APIs, sterile drug product, and biologics platforms.